A biopharmaceutical company focused on oncology.

Hormone refractoryal Data from Picoplatin Trials In a variety of tumor types at American Society of Clinical Oncology 2008 Annual Meeting PresentationPoniard Pharmaceuticals , a biopharmaceutical company focused on oncology, today announced that the company will present clinical trials clinical trials of picoplatin, in various tumor types and combinations, at poster sessions during the 44th Annual Meeting of the American Society of Clinical Oncology in Chicago’s McCormick Place. The company is preliminary data from the ongoing Phase 2 clinical trial with picoplatin in colorectal cancer and updated data from the Phase 1 CRC study data from the ongoing Phase 2 trial of picoplatin in hormone-refractory prostate cancer to present.

The Company’s actual results to differ materially from those that are associated with these forward-looking statements on a number of factors, including risks and uncertainties associated with the Company’s research and development activities specified the results of pre – clinical development of the receipt and timing of regulatory approvals, market acceptance of the Company’s products on offer, the company expected operating losses, need for future capital and ability to obtain future financing, competition from third parties, and the ability to get the company and protect intellectual property rights, the Company’s dependence on third-party manufacturers and suppliers, the company’s lack of sales and marketing experience, the Company’s ability to attract and retain, changes in technology, government regulation and general market conditions and the risks and uncertainties described in the Company’s current and periodic filings with the Securities and Exchange Commission , including the company’s Annual Report on Form 10 – K for the year ended 31 December 2007 and Quarterly Report on Form 10-Q for the quarter ended 31 March 2008.Johansson therefore considers it important to the health care system be assisting talking for after treatment, where the main focus at the couple provide times – a man and that women – reactions and thoughts about infertility and future. I also believe that the healthcare should strive to the group have failed into the IVF treatment, can to reduce In some instances so by the couple accept a number of other various health treatments, says Johansson. Approximately 9 percent of unwanted childlessness.

Other articles from category "healthcare":

Random articles